-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Apixaban in Stroke
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Apixaban in Stroke report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Apixaban in Stroke Drug Details: Apixaban is under development for the treatment of...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – MP-0317 in Head And Neck Cancer Squamous Cell Carcinoma
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - MP-0317 in Head And Neck Cancer Squamous Cell Carcinoma report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data.MP-0317 in Head And Neck Cancer Squamous Cell...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Suvratoxumab in Staphylococcus aureus Infections
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Suvratoxumab in Staphylococcus aureus Infections report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data.Suvratoxumab in Staphylococcus aureus Infections Drug Details:Suvratoxumab (MEDI-4893) is under development for...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Panaecin in Cystic Fibrosis
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Panaecin in Cystic Fibrosis report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Panaecin in Cystic Fibrosis Drug Details: Panaecin (gallium citrate) is under development...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Sirexatamab in Colorectal Cancer
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Sirexatamab in Colorectal Cancer report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data.Sirexatamab in Colorectal Cancer Drug Details: Sirexatamab (DKN-01, LY-2812176) is under development for...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Tosatoxumab in Ventilator Associated Pneumonia (VAP)
OverviewHow likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalDatas proprietary machine learning algorithms developed using over 10 years of historical data.Tosatoxumab in Ventilator Associated Pneumonia (VAP) Drug Details:AR-301 (KBSA301) is under development for the treatment of...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Volasertib in Myelodysplastic Syndrome
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Volasertib in Myelodysplastic Syndrome report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data.Volasertib in Myelodysplastic Syndrome Drug Details:Volasertib (BI 6727) is under development for the...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Tosatoxumab in Hospital Acquired Pneumonia (HAP)
OverviewHow likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalDatas proprietary machine learning algorithms developed using over 10 years of historical data.Tosatoxumab in Hospital Acquired Pneumonia (HAP) Drug Details:AR-301 (KBSA301) is under development for the treatment of...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Tozorakimab in Diabetic Nephropathy
OverviewHow likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalDatas proprietary machine learning algorithms developed using over 10 years of historical data.Tozorakimab in Diabetic Nephropathy Drug Details: Tozorakimab (MEDI-3506) is under development for the treatment of diabetic kidney...